Versant Venture Management LLC's Q3 2026 13F: 1 new position, 1 exit
Form 13F-HR for the quarter ended Sep 30, 2026 · filed Nov 13, 2026 · 8 reported positions · accession 0001193125-26-460919
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Increased | Contineum Therapeutics, Inc. (CTNM) | 5.5% | 15.9% | +10.4 pts | +750K sh | +138% |
| Exited | Skye Bioscience, Inc. (SKYE) | 0.9% | — | −0.9 pts | −2.01M sh | −100% |
| New | Skye Bioscience, Inc. (SKYEZZZZ) | — | 0.4% | +0.4 pts | +251K sh | new |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 100.0% of the equity book
Changes in the top 10 this quarter: SKYEZZZZ entered · SKYE left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | Monte Rosa Therapeutics, Inc. (GLUE) | 47.3% | 34.8% | |
| 2 | Century Therapeutics, Inc. (IPSC) | 18.3% | 19.1% | |
| 3 | Contineum Therapeutics, Inc. (CTNM) | 5.5% | 15.9% | |
| 4 | Jade Biosciences, Inc. (JBIO) | 13.6% | 12.8% | |
| 5 | Lenz Therapeutics, Inc. (LENZ) | 9.3% | 9.4% | |
| 6 | CRISPR Therapeutics AG (CRSP) | 5.0% | 7.5% | |
| 7 | Skye Bioscience, Inc. (SKYEZZZZ) | 0.0% | 0.4% | Entered the top 10 |
| 8 | Tempest Therapeutics, Inc. (TPST) | 0.2% | 0.2% | |
| — | Skye Bioscience, Inc. (SKYE) | 0.9% | 0.0% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).